NCT00260351View on ClinicalTrials.gov

Immunogenicity and Safety of Verorab™ in Indian Population

PHASE4CompletedINTERVENTIONAL
Enrollment

405

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

August 31, 2008

Study Completion Date

October 31, 2008

Conditions
Rabies
Interventions
BIOLOGICAL

Purified Verocell Rabies Vaccine

0.1 mL, ID (TRC regimen)

BIOLOGICAL

Purified Verocell Rabies Vaccine

0.5 mL, IM (ZAGREB regimen)

BIOLOGICAL

Purified Verocell Rabies Vaccine

0.5 mL, IM (ESSEN regimen)

Trial Locations (3)

Unknown

Hyderabad

Kolkata

Lucknow

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00260351 - Immunogenicity and Safety of Verorab™ in Indian Population | Biotech Hunter | Biotech Hunter